Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Merck
Dow
Harvard Business School
AstraZeneca

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Synthon Pharms Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for SYNTHON PHARMS, and what generic alternatives to SYNTHON PHARMS drugs are available?

SYNTHON PHARMS has twelve approved drugs.

There is one US patent protecting SYNTHON PHARMS drugs. There are three tentative approvals on SYNTHON PHARMS drugs.

There are four patent family members on SYNTHON PHARMS drugs in four countries and thirty-four supplementary protection certificates in ten countries.

Summary for Synthon Pharms
International Patents:4
US Patents:1
Tradenames:10
Ingredients:10
NDAs:12

Drugs and US Patents for Synthon Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Synthon Pharms ZOLPIDEM TARTRATE zolpidem tartrate TABLET;ORAL 077540-001 Apr 23, 2007 DISCN No No   Start Trial   Start Trial
Synthon Pharms RISPERIDONE risperidone TABLET;ORAL 078187-001 Oct 22, 2009 DISCN No No   Start Trial   Start Trial
Synthon Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET;ORAL 077080-001 Jun 27, 2007 DISCN No No   Start Trial   Start Trial
Synthon Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET;ORAL 077080-002 Jun 27, 2007 DISCN No No   Start Trial   Start Trial
Synthon Pharms SIMVASTATIN simvastatin TABLET, ORALLY DISINTEGRATING;ORAL 021961-004 Oct 9, 2007 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Premature patent expirations for SYNTHON PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
  Start Trial   Start Trial

Supplementary Protection Certificates for Synthon Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2236132 122015000006 Germany   Start Trial PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
2236132 C300714 Netherlands   Start Trial PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
0720599 26/2005 Austria   Start Trial PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402
0503785 C300375 Netherlands   Start Trial PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
0296749 97C0023 France   Start Trial PRODUCT NAME: ANASTROZOLE, EVENTUELLEMENT SOUS LA FORME D UN SEL D ADDITION ACCEPTABLE EN MEDECINE PHARMACEUTIQUE; NAT REG. NO/DATE: NL 21126 19961227; FIRST REG.: 12619/0106 19950811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKinsey
Merck
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.